DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hodgkin's Disease

Intervention: Pulmonary Function Tests (Procedure); CAT Scan (Procedure)

Phase: N/A

Status: Completed

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Andrea K. Ng, MD, MPH, Principal Investigator, Affiliation: Dana-Farber Cancer Institute

Summary

The purpose of this study is to find out the impact Bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.

Clinical Details

Official title: A Prospective Study of Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy With or Without Mediastinal Irradiation

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Pulmonary function

Detailed description:

- The tests and procedures in this study are part of regular cancer care but this study

offers more structured timing of these standard tests.

- Due to the potential lung toxicity associated with bleomycin-based chemotherapy,

pulmonary function tests are routinely performed. Pulmonary function tests will be performed by a licensed, registered respiratory therapist and performed prior to the beginning of treatment, between the chemotherapy and radiation therapy (only for patients receiving both chemotherapy and radiation therapy), and at approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments.

- A CAT scan will be performed prior to the beginning of treatment, and approximately 1

month, 6 months, 1 year and 2 years after the completion of all treatments.

- A self-administered questionnaire will be performed on the days the patient is

undergoing pulmonary function tests.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with newly diagnosed classical Hodgkin's disease, with mediastinal

involvement

- Bleomycin-based chemotherapy alone or in combination with mediastinal irradiation

Exclusion Criteria:

- Prior chest irradiation

- Mediastinal irradiation received at an outside institution

- Refractory or progressive disease on treatment

Locations and Contacts

Brigham and Women's Hospital, Boston, Massachusetts 02115, United States

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Additional Information

Starting date: October 2001
Last updated: December 19, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017